Trial Profile
An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Cholangiocarcinoma
- Focus Adverse reactions
- 09 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Apr 2013 Planned end date changed from 1 Jun 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
- 24 May 2012 Planned End Date changed from 1 Dec 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.